Nephrol Dial Transplant (2003) 18: 353-361
© 2003 European Renal Association-European Dialysis and Transplant Association
A randomized controlled trial of haemoglobin normalization with epoetin alfa in pre-dialysis and dialysis patients
1 Department of Medical Sciences, University Hospital, Uppsala, 2 Department of Renal Medicine, Skaraborgs Hospital, Skövde, 3 Department of Nephrology and Transplantation, University Hospital, Malmö and 4 Department of Nephrology, Varberg Hospital, Varberg, Sweden
Background. Partial correction of renal anaemia with erythropoietin improves quality of life (QoL). We aimed to examine if normalization of haemoglobin with epoetin alfa in pre-dialysis and dialysis patients further improves QoL and is safe.
Methods. 416 Scandinavian patients with renal anaemia [pre-dialysis, haemodialysis (HD) and peritoneal dialysis patients] were randomized to reach a normal haemoglobin of 135–160 g/l (n=216) or a subnormal haemoglobin of 90–120 g/l (n=200) with or without epoetin alfa. Study duration was 48–76 weeks. QoL was measured using Kidney Disease Questionnaires in 253 Swedish dialysis patients. Safety was examined in all patients.
Results. QoL improved, measured as a decrease in physical symptoms (P=0.02), fatigue (P=0.05), depression (P=0.01) and frustration (P=0.05) in the Swedish dialysis patients when haemoglobin was normalized. In pre-dialysis patients, diastolic blood pressure was higher in the normal compared with the subnormal haemoglobin group after 48 weeks. However, the progression rate of chronic renal failure was comparable. In the normal haemoglobin group (N-Hb), 51% had at least one serious adverse event compared with 49% in the subnormal haemoglobin group (S-Hb) (P=0.32). The incidence of thrombovascular events and vascular access thrombosis in HD patients did not differ. The mortality rate was 13.4% in the N-Hb group and 13.5% in the S-Hb group (P=0.98). Mortality decreased with increasing mean haemoglobin in both groups.
Conclusions. Normalization of haemoglobin improved QoL in the subgroup of dialysis patients, appears to be safe and can be considered in many patients with end-stage renal disease.
Keywords: anaemia; end-stage renal failure; erythropoietin; haemoglobin; mortality; quality of life
Correspondence and offprint requests to: Hans Furuland, MD, Department of Internal Medicine, University Hospital, Entrance 40, S-751 85 Uppsala, Sweden. Email: hans.furuland{at}medsci.uu.se
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  F. M. Clement, S. Klarenbach, M. Tonelli, J. A. Johnson, and B. J. Manns The Impact of Selecting a High Hemoglobin Target Level on Health-Related Quality of Life for Patients With Chronic Kidney Disease: A Systematic Review and Meta-analysis Arch Intern Med, June 22, 2009; 169(12): 1104 - 1112. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. N. Foley, B. M. Curtis, and P. S. Parfrey Erythropoietin Therapy, Hemoglobin Targets, and Quality of Life in Healthy Hemodialysis Patients: A Randomized Trial Clin. J. Am. Soc. Nephrol., April 1, 2009; 4(4): 726 - 733. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Hayat Safety Issues With Intravenous Iron Products in the Management of Anemia in Chronic Kidney Disease Clin. Med. Res., December 1, 2008; 6(3-4): 93 - 102. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Yang, R. K. Israni, S. M. Brunelli, M. M. Joffe, S. Fishbane, and H. I. Feldman Hemoglobin Variability and Mortality in ESRD J. Am. Soc. Nephrol., December 1, 2007; 18(12): 3164 - 3170. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Fishbane and A. Besarab Mechanism of Increased Mortality Risk with Erythropoietin Treatment to Higher Hemoglobin Targets Clin. J. Am. Soc. Nephrol., November 1, 2007; 2(6): 1274 - 1282. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. B. Wish and D. W. Coyne Use of Erythropoiesis-Stimulating Agents in Patients With Anemia of Chronic Kidney Disease: Overcoming the Pharmacological and Pharmacoeconomic Limitations of Existing Therapies Mayo Clin. Proc., November 1, 2007; 82(11): 1371 - 1380. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. M. West, K. Harris, M. S. Gilthorpe, C. Tolman, and E. J. Will Functional Data Analysis Applied to a Randomized Controlled Clinical Trial in Hemodialysis Patients Describes the Variability of Patient Responses in the Control of Renal Anemia J. Am. Soc. Nephrol., August 1, 2007; 18(8): 2371 - 2376. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. H. Horl, Y. Vanrenterghem, P. Aljama, P. Brunet, R. Brunkhorst, L. Gesualdo, I. Macdougall, C. Wanner, and B. Wikstrom OPTA: Optimal treatment of anaemia in patients with chronic kidney disease (CKD) Nephrol. Dial. Transplant., June 1, 2007; 22(suppl_3): iii20 - iii26. [Full Text] [PDF]
|
|
|
|
|
|
J. Rossert, C. Gassmann-Mayer, D. Frei, and W. McClellan Prevalence and predictors of epoetin hyporesponsiveness in chronic kidney disease patients Nephrol. Dial. Transplant., March 1, 2007; 22(3): 794 - 800. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. H. Horl Clinical Aspects of Iron Use in the Anemia of Kidney Disease J. Am. Soc. Nephrol., February 1, 2007; 18(2): 382 - 393. [Full Text] [PDF]
|
|
|
|
|
|
D. W. Coyne Influence of Industry on Renal Guideline Development Clin. J. Am. Soc. Nephrol., January 1, 2007; 2(1): 3 - 7. [Full Text] [PDF]
|
|
|
|
|
|
F. Locatelli, L. Del Vecchio, and P. Pozzoni Anemia and Cardiovascular Risk: The Lesson of the CREATE Trial J. Am. Soc. Nephrol., December 1, 2006; 17(12_suppl_3): S262 - S266. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. B. Drueke, F. Locatelli, N. Clyne, K.-U. Eckardt, I. C. Macdougall, D. Tsakiris, H.-U. Burger, A. Scherhag, and the CREATE Investigators Normalization of Hemoglobin Level in Patients with Chronic Kidney Disease and Anemia N. Engl. J. Med., November 16, 2006; 355(20): 2071 - 2084. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. K. Singh, L. Szczech, K. L. Tang, H. Barnhart, S. Sapp, M. Wolfson, D. Reddan, and the CHOIR Investigators Correction of Anemia with Epoetin Alfa in Chronic Kidney Disease N. Engl. J. Med., November 16, 2006; 355(20): 2085 - 2098. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. N. Foley Do We Know the Correct Hemoglobin Target for Anemic Patients with Chronic Kidney Disease? Clin. J. Am. Soc. Nephrol., July 1, 2006; 1(4): 678 - 684. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. L. Roberts, R. N. Foley, E. D. Weinhandl, D. T. Gilbertson, and A. J. Collins Anaemia and mortality in haemodialysis patients: interaction of propensity score for predicted anaemia and actual haemoglobin levels Nephrol. Dial. Transplant., June 1, 2006; 21(6): 1652 - 1662. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Paoletti and G. Cannella Update on Erythropoietin Treatment: Should Hemoglobin Be Normalized in Patients with Chronic Kidney Disease? J. Am. Soc. Nephrol., April 1, 2006; 17(4_suppl_2): S74 - S77. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. K. Port, R. L. Pisoni, J. Bommer, F. Locatelli, M. Jadoul, G. Eknoyan, K. Kurokawa, B. J. Canaud, M. P. Finley, and E. W. Young Improving Outcomes for Dialysis Patients in the International Dialysis Outcomes and Practice Patterns Study Clin. J. Am. Soc. Nephrol., March 1, 2006; 1(2): 246 - 255. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Garrancho, J. Kirchgessner, M. Arranz, G. Klinkner, R. Rentero, J. A. Ayala, and D. Marcelli Haemoglobin level and vascular access survival in haemodialysis patients Nephrol. Dial. Transplant., November 1, 2005; 20(11): 2453 - 2457. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. A. Zakai, R. Katz, C. Hirsch, M. G. Shlipak, P. H. M. Chaves, A. B. Newman, and M. Cushman A Prospective Study of Anemia Status, Hemoglobin Concentration, and Mortality in an Elderly Cohort: The Cardiovascular Health Study Arch Intern Med, October 24, 2005; 165(19): 2214 - 2220. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. S. Parfrey, R. N. Foley, B. H. Wittreich, D. J. Sullivan, M. J. Zagari, D. Frei, and for the Canadian European Study Double-Blind Comparison of Full and Partial Anemia Correction in Incident Hemodialysis Patients without Symptomatic Heart Disease J. Am. Soc. Nephrol., July 1, 2005; 16(7): 2180 - 2189. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Grzeszczak, W. Sulowicz, B. Rutkowski, A. F. de Vecchi, R. Scanziani, P.-Y. Durand, A. Bajo, V. Vargemezis, and on behalf of the European Collaborative Group The efficacy and safety of once-weekly and once-fortnightly subcutaneous epoetin {beta} in peritoneal dialysis patients with chronic renal anaemia Nephrol. Dial. Transplant., May 1, 2005; 20(5): 936 - 944. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. F.M. Strippoli, J. C. Craig, C. Manno, and F. P. Schena Hemoglobin Targets for the Anemia of Chronic Kidney Disease: A Meta-analysis of Randomized, Controlled Trials J. Am. Soc. Nephrol., December 1, 2004; 15(12): 3154 - 3165. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. R. Aronoff Safety of Intravenous Iron in Clinical Practice: Implications for Anemia Management Protocols J. Am. Soc. Nephrol., December 1, 2004; 15(suppl_2): S99 - S106. [Full Text] [PDF]
|
|
|
|
|
|
D. Van Wyck, J. Anderson, and K. Johnson Labile iron in parenteral iron formulations: a quantitative and comparative study Nephrol. Dial. Transplant., March 1, 2004; 19(3): 561 - 565. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Cotter Does the Evidence for Anemia Treatment Support a Survival Benefit? Arch Intern Med, October 27, 2003; 163(19): 2395 - 2396. [Full Text] [PDF]
|
|